Burkholderia thailandensis E264/pBMTL3-tdpR发酵生产抗癌药物ThailandepsinA的研究

在伯克氏菌Bth264野生株产新型抗癌药物Thailandepsin A以及调节基因tdp R正向调控Thailandepsin A生物合成的基础上,利用基因工程菌Bth264/p BMTL3-tdp R发酵生产Thailandepsin A,以提高产量。以0.5%乳糖为诱导剂,确定最佳诱导条件:发酵15 h添加乳糖,诱导时间6 h;通过单因素实验,确定葡萄糖和胰蛋白胨作为碳氮源、装液量65/250 m L以及接种量1%;同时结合优化发酵培养基进行发酵,Thailandepsin A产量达到252.14 mg·L-1,比优化前的产量提高56%;另外在发酵过程中,添加大孔树脂HP-20原位吸附产物,Thailandepsin A产量可达283.75 mg·L-1,比不加树脂提高13.8%;最后,基于RT-PCR和比较Ct值法,基因工程菌和野生菌相比,Thailandepsin A生物合成基因tdp B、tdp C1的转录水平分别提高11.4倍和6.0倍,对应的产量增加4.6倍,从而在很大程度上说明调节基因tdp R的过表达促进生物合成基因转录水平的提高以及产量的增加。     

Analysis of Phytochemical Composition of Camellia oleifera Oil and Evaluation of its Anti-Inflammatory Effect in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages

In China, Camellia oleifera oil (COO) is not only a common edible oil but also a traditional remedy widely applied to ameliorate a variety of illnesses associated with inflammation, such as mouth ulcers, thrush, eczema, etc. However, there has been a lack of relevant biological research on the anti-inflammatory capacity of COO, and the specific bioactive lipid phytochemicals contributing to the anti-inflammatory effect need further research. In this study, the RAW 264.7 macrophages model was used to investigate the anti-inflammatory capacity of COO. Our data showed that 33–200 μg/mL COO markedly inhibited the lipopolysaccharide lipopolysaccharide (LPS)-stimulated nitric oxide (NO.) secretion via the suppression of Nos2 and Cox-2 expression. The enzyme immunoassay confirmed that COO also exhibited a strong suppressive effect on the expression of proinflammatory cytokines such as Tnf-α and Il-6. To further explore the correlation between the anti-inflammatory effects and the lipid phytochemicals in COO, 10 samples were collected and screened for their chemical compositions. It was interestingly demonstrated that the polyphenol extracts of COO play a vital role in its anti-inflammatory properties. In addition, an oil-in-water (O/W) emulsion-based system was also developed to deliver the liposoluble COO into the cells, and the feasibility of this system was confirmed. Our research confirms the anti-inflammatory potential of COO and highlights that the main functional ingredient is polyphenol extracts. This may provide a scientific basis for the comprehensive utilization and development of COO and related functional foods.     

基于FPGA的CAVLC编解码器设计与实现

H．264标准在基本档次和扩展档次中采用CAVLC熵编码，完成对变换系数残差块的编码。提出一种基于FPGA的H．264标准的CAVLC编解码器，程序代码用verilog硬件描述语言编写，并在QuartusⅡ中进行了仿真验证，可以实现对每个残差块数据的编解码并将其按照宏块光栅扫描的顺序输出到存储器，因此适合于嵌入在最终的码流中。仿真结果表明此CAVLC编解码器达到H．264标准中基本档次和扩展档次level3．0的性能要求。     

H.264变换编码与量化原理及优化研究

本文分析了H.264视频编码标准中的整数变换和量化过程。H.264采用从DCT变换演化而来的4×4整数变换,使变换算法复杂度减小,同时消除了浮点运算导致的失配现象。将尺度调整融合在量化过程中,减少乘法次数,使H.264标准相对于以前的编码标准更加有效。同时通过采用SSE2指令,实现H.264变换与量化的优化算法,实验结果表明此算法有效地提高了编码速度。     

H.264变换编码与量化原理分析

详细分析了 H .2 64视频编码标准中的整数变换和量化过程。 H .2 64采用 4× 4整数变换 ,并将尺度调整融合在量化过程中 ,降低变换算法复杂度和减少乘法次数 ,相对于以前的编码标准更加有效     

Grouped Approach for the Design of H.264/AVC Motion Estimation Architectures

This letter presents a novel approach for organizing computational resources into groups within H.264/AVC motion estimation architectures, leading to reductions of up to 75% in the equivalent gate count with respect to state‐of‐the‐art designs.     

H.264/AVC可伸缩扩展集

可伸缩视频编码是目前国际上研究的热点。联合视频组（JVT）在过去的一年中围绕SVC展开了大量的研究工作，提出了作为H.264／AVC扩展集的SVC方案。实现了时间、空间和质量（SNR）的可伸缩性。本文介绍H.264／AVC可伸缩扩展集的基本结构和技术要点。     

视频编码新标准H.264中抗误码技术的研究

介绍了视频编码新标准———H .2 6 4中采用的几种抗误码技术 ,基于这些技术 ,新标准确保了压缩视频流在接收端的恢复质量。     

基于BCM3540的高清晰度数字电视机顶盒的硬件设计

介绍一种基于BCM3540的高清晰度数字电视机顶盒的硬件设计方案,该方案采用1块主芯片BCM3540及1块协处理器BCM7411,能够处理MPEG-2高清、标清以及H.264高清、标清信号,可以直接支持PCMCIA接口实现机卡分离,并具有32位PCI总线,可以很方便地进行功能扩展。